Literature DB >> 6274794

Augmentation of the antibody forming cell response to neuraminidase-treated cells by myxoviruses.

P H Russell.   

Abstract

Following the inoculation of Newcastle Disease virus, Sendai virus and influenza virus CBA mice made a specific plaque-forming cell response to virus-treated sheep red blood cells but not to virus-treated L1210 cells. This non-specific response to virus-treated L1210 could be exactly reproduced by treatment of L1210 with bacterial neuraminidase. Neuraminidase-treated cells from eight of nine vertebrates including chickens and syngeneic mice also registered plaques. Inoculations of the above viruses were considered to have evoked separate antibody forming cell responses to viral antigens, foreign cell components in the virus inoculum and to neuraminidase revealed cell membrance antigens.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274794      PMCID: PMC1554997     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  A novel subset of antigenic cells triggers B-cell responses to MHC antigens.

Authors:  I Nakashima; P Lake
Journal:  Nature       Date:  1979-06-21       Impact factor: 49.962

2.  Effect of trypsin on reproduction of type 4 parainfluenza virus in Vero cell cultures under fluid overlay.

Authors:  Y Morimoto; Y Doi; H Ito
Journal:  Jpn J Med Sci Biol       Date:  1970-02

Review 3.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

4.  Murine autoantibodies to a cryptic membrane antigen; possible explanation for neuraminidase-induced increase in cell immunogenicity.

Authors:  S A Rosenberg; S Schwarz
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

5.  Requirement for antigen in lipopolysaccharide-dependent induction of B cells.

Authors:  P A Bretscher
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

6.  Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.

Authors:  M D Kazatchkine; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

7.  Increase in titer of the naturally occurring human antibody to neuraminidase-treated lymphocytes after influenza.

Authors:  G N Rogentine; C M Doherty; S H Pincus
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

8.  The guinea-pig complement-activating lymphocyte surface component (GPCA): a mouse T-cell marker distinct from Thy-1.

Authors:  F Kierszenbaum; D B Budzko
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

9.  Detection of cells producing surface antigen-specific antibody to influenza viruses.

Authors:  C McLaren; G E Grubbs; F A Ennis
Journal:  J Clin Microbiol       Date:  1978-10       Impact factor: 5.948

10.  Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway.

Authors:  L H Perrin; B S Joseph; N R Cooper; M B Oldstone
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

  10 in total
  3 in total

1.  The synergistic neutralization of Newcastle disease virus by two monoclonal antibodies to its haemagglutinin-neuraminidase protein.

Authors:  P H Russell
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Newcastle disease virus and two influenza viruses: differing effects of acid and temperature on the uptake of infectious virus into bovine and canine kidney cell lines.

Authors:  P H Russell
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

3.  Monoclonal antibodies against avian paramyxovirus-3: antigenic mapping and functional analysis of the haemagglutinin-neuraminidase protein and the characterization of nonspecific monoclonal antibodies.

Authors:  C L Anderson; P H Russell
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.